Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BELLUS Health Inc. (T:BLU)

Business Focus: Biotechnology & Medical Research

Jul 06, 2020 02:15 pm ET
IIROC Trade Resumption - BLU
TORONTO, July 6, 2020 /CNW/ - Trading resumes in:
Jul 06, 2020 02:09 pm ET
IIROC Trading Halt - BLU
TORONTO, July 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 06, 2020 01:35 pm ET
IIROC Trade Resumption - BLU
TORONTO, July 6, 2020 /CNW/ - Trading resumes in:
Jul 06, 2020 01:29 pm ET
IIROC Trading Halt - BLU
TORONTO, July 6, 2020 /CNW/ - The following issues have been halted by IIROC:
Jul 06, 2020 07:00 am ET
BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough.
May 28, 2020 07:00 am ET
BELLUS Health to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
May 14, 2020 05:00 pm ET
BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the first quarter ended March 31, 2020.
May 13, 2020 07:00 am ET
BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a virtual Key Opinion Leader (“KOL”) meeting to discuss the chronic cough landscape on Wednesday, May 27, 2020 at 9:00 a.m. EDT.
May 06, 2020 07:00 am ET
BELLUS Health to Present at the BofA Securities Virtual Health Care Conference
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Tuesday, May 12, 2020 at the BofA Securities Virtual Health Care Conference.
May 05, 2020 05:00 pm ET
BELLUS Health Announces Change to Annual and Special Shareholder Meeting Format
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced a format change to its upcoming annual and special meeting of shareholders (the “AGM”) being held on Thursday, May 14, 2020, at 2:30 p.m. ET.
Apr 06, 2020 05:00 pm ET
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment. The Company decided to close the trial early due to the impact of the COVID-19 pandemic on the RELIEF clinical trial activities. The Company continues to expect topline data fr
Mar 25, 2020 02:07 pm ET
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) is pleased to announce that it has closed the transaction announced on March 23, 2020 (the “Transaction”) in accordance with the asset purchase and sale agreement entered into with adMare BioInnovations’ NEOMED Institute (“adMare”).
Mar 23, 2020 07:31 am ET
BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has entered into an asset purchase and sale agreement to acquire all of the remaining BLU-5937 and related P2X3 antagonists intellectual property assets (the “BLU-5937 Assets”) from adMare BioInnovations’ NEOMED Institute (“adMare”) (the “Transaction”).
Mar 19, 2020 10:43 am ET
IIROC Trade Resumption - BLU
TORONTO, March 19, 2020 /CNW/ - Trading resumes in:
Mar 19, 2020 10:28 am ET
IIROC Trading Halt - BLU
TORONTO, March 19, 2020 /CNW/ - The following issues have been halted by IIROC:
Mar 19, 2020 07:00 am ET
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.
Feb 27, 2020 05:00 pm ET
BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ended December 31, 2019.
Feb 20, 2020 07:00 am ET
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.
Nov 14, 2019 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the third quarter ended September 30, 2019.
Nov 13, 2019 07:00 am ET
BELLUS Health to Present at Jefferies Global Healthcare Conference in London
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.
Sep 17, 2019 08:57 am ET
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the underwriters of its previously announced underwritten public offering (the “Offering”) of common shares have partially exercised their option to purchase additional common shares, resulting in the issuance of an additional 1,320,296 common shares of the Company at a price of US$7.10 per common share for additional gross proceeds to the Co
Sep 09, 2019 09:09 am ET
BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United States
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 9,859,155 common shares at a price to the public of US$7.10 per common share, for total gross proceeds of approximately US$70 million, before deducting the underwriting commissions and any expenses related to the Offering
Sep 05, 2019 07:00 am ET
BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United States
In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Cowen and Guggenheim Securities, as joint book-running managers, Baird, as lead manager, and Bloom Burton Securities, as co-manager (collectively, the “Underwriters”). The Underwriters have agreed to purchase 9,859,155 common shares at a price of US$7.10 per common share (C$9.40 per co
Sep 03, 2019 08:05 am ET
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated July 26, 2019 (the “Base Prospectus”) in connection with a proposed US$60 million public offering of its common shares (the “Offering”), and the filing of an application to list its common shares on the Nasdaq Global Market (“Nasdaq”) in the United States under the ticker “BLU”. Trading of the Company’s common shares is expected to commence on the Nasdaq following the pricing of the Offering. The Sup
Aug 26, 2019 07:00 am ET
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of Dr. Catherine Bonuccelli, MD to the role of Chief Medical Officer. Dr. Bonuccelli is a pediatric pulmonologist that brings over 20 years of pharmaceutical experience with significant expertise in clinical and product development of respiratory and non-respiratory products.
Aug 15, 2019 07:00 am ET
BELLUS Health Announces Share Consolidation
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it is proceeding with a 3.6:1 consolidation of the Company’s common shares (the “Consolidation”) with an effective date of August 19, 2019. Notice has been provided to the Toronto Stock Exchange (the “TSX”) and BELLUS Health’s common shares are expected to begin trading on the TSX, on a consolidated basis, on or about August 19, 2019.
Aug 08, 2019 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2019. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jul 30, 2019 07:00 am ET
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been enrolled in the RELIEF (A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refract
Jul 15, 2019 07:00 am ET
BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, 2019 in New York City. The event will include discussions on the unmet medical need in the category, and a review of current therapies in development including P2X3 antagonists. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagon
May 21, 2019 12:15 pm ET
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today presented results from the clinical Phase 1 study of BLU-5937, an orally-administered P2X3 antagonist, being developed for the treatment of refractory chronic cough. Clinical data presented at the American Thoracic Society International Conference in Dallas, Texas showed that BLU-5937 is well-tolerated and importantly, pr
May 15, 2019 07:00 am ET
BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.
May 08, 2019 05:00 pm ET
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019
BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today provided an update on BLU-5937, its lead drug candidate for refractory chronic cough, and reported its financial and operating results for the first quarter ended March 31, 2019. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Apr 04, 2019 07:00 am ET
BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
LAVAL, QC, April 4, 2019 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at two upcoming healthcare investor conferences.
Apr 03, 2019 07:00 am ET
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients
- Phase 2 Study for Potential Best-in-Class Therapeutic for Refractory Chronic Cough Patients Expected to Start in Mid-2019 -
Feb 21, 2019 06:00 am ET
BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
- Reports Financial and Operating Results for the Year Ended December 31, 2018 -
Dec 28, 2018 07:00 am ET
BELLUS Health Announces Payment of $134,149 to Thallion CVR Holders
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical needs, today announced that it will pay an amount of $134,149 to the...
Dec 18, 2018 08:53 am ET
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has closed an equity offering, issuing a total of 36,842,105 common shares for gross proceeds of $35 million (the...
Dec 11, 2018 09:32 am ET
BELLUS Health Announces Pricing of $35 Million Public Offering of Common Shares
BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced the pricing of its overnight marketed equity...
Dec 11, 2018 09:02 am ET
IIROC Trade Resumption - BLU
TORONTO, Dec. 11, 2018 /CNW/ - Trading resumes in:
Dec 11, 2018 08:58 am ET
IIROC Trading Halt - BLU
TORONTO, Dec. 11, 2018 /CNW/ - The following issues have been halted by IIROC:
Dec 10, 2018 05:01 pm ET
BELLUS Health Announces Overnight Marketed Equity Offering
BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that it will undertake an overnight marketed...
Nov 19, 2018 04:00 pm ET
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937
BELLUS Health Inc. (TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced positive top-line results from the clinical Phase...
Nov 14, 2018 04:00 pm ET
BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018
- Reports Financial and Operating Results for the Third Quarter Ended September 30, 2018 -
Sep 25, 2018 07:00 am ET
BELLUS Health Announces Appointment of Clinical Advisory Board
-Team of Internationally-Renowned Cough Experts to Guide BLU-5937 Clinical Development Strategy-
Aug 30, 2018 07:00 am ET
BELLUS Health to Present at Baird 2018 Global Healthcare Conference
LAVAL, QC, Aug. 30, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including its lead program BLU-5937 for the treatment of chronic cough, on Thursday September 6, 2018 at 2:00 pm ET at the Baird 2018 Global Healthcare Conference in New York.
Aug 08, 2018 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018
- Data from Ongoing Phase 1 Study for Lead Drug Candidate BLU-5937 Expected in Q4 2018 -
Jul 19, 2018 07:00 am ET
BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
- Grant of Japanese Patent Expands Portfolio That Also Includes United States, Europe and China -
Jul 09, 2018 07:30 am ET
Jul 09, 2018 07:30 am ET
Jun 27, 2018 11:30 am ET
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
- Preclinical Data Highlights BLU-5937 as a Potential Best-In-Class Treatment for Chronic Cough -- First In-Human Study to Begin in July 2018 - 
Jun 20, 2018 07:00 am ET
BELLUS Health to Present at the 2018 International Cough Symposium
LAVAL, QC, June 20, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present the Company's lead drug candidate for the treatment of chronic cough, BLU-5937, at the 2018 International Cough Symposium in London, UK, on Wednesday June 27, 2018 at 4:30 pm BST (11:30 am EDT).
May 15, 2018 04:21 pm ET
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018
- Completed studies required to submit clinical trial application for BLU-5937 for chronic cough -- Announces voting results from Annual Meeting -
Apr 30, 2018 02:27 pm ET
BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity
LAVAL, QC, April 30, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today responded to a request from the Investment Industry Regulatory Organization of Canada (IIROC) to comment on recent trading activity of BELLUS Health's shares.
Apr 26, 2018 07:00 am ET
BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 26, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including an update on its lead program, BLU-5937 for the treatment of chronic cough, on Thursday May 3, 2018 at 9:30 am ET at the 2018 Bloom Burton & Co. Healthcare Investor Conference.
Feb 21, 2018 06:00 am ET
BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
LAVAL, QC, Feb. 21, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2017. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jan 09, 2018 06:00 am ET
BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
LAVAL, QC, Jan. 9, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that it has received from Taro Pharmaceuticals Inc. ("Taro") a milestone payment of $400,000 in relation to the sale of its wholly-owned subsidiary Thallion Pharmaceuticals Inc. ("Thallion") in March 2017.
Jan 04, 2018 06:00 am ET
BELLUS Health to Present at Biotech Showcase™ 2018 Conference
LAVAL, QC, Jan. 4, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will provide a corporate overview of the Company, including BLU-5937, its lead program for chronic cough, at the upcoming Biotech Showcase™ 2018 Conference on Tuesday, January 9 at 9:30 am PT (12:30 pm ET) in San Francisco, CA, at the Hilton San Francisco Union Square.
Dec 12, 2017 07:29 am ET
BELLUS Health Closes $20M Common Share Financing
- Proceeds to Support Advancing BLU-5937 for Chronic Cough into Clinical Testing -
Dec 05, 2017 09:27 am ET
IIROC Trade Resumption - BELLUS Health Inc.
Toronto, Ontario--(Newsfile Corp. - December 5, 2017) - Trading resumes in:
Dec 05, 2017 09:25 am ET
IIROC Trade Halt - BELLUS Health Inc.
Toronto, Ontario--(Newsfile Corp. - December 5, 2017) - The following issues have been halted by IIROC:
Nov 08, 2017 07:00 am ET
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
LAVAL, QC, Nov. 8, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the third quarter ended September 30, 2017. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Sep 27, 2017 08:00 am ET
BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors
LAVAL, QC, Sept. 27, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that biotech entrepreneur Dr. Clarissa Desjardins is joining its Board of Directors.
Sep 20, 2017 08:00 am ET
BELLUS Health Chronic Cough Webcast Taking Place Today
- BELLUS to provide BLU-5937 program update, Key Opinion Leader Dr. Jacky Smith to present on chronic cough -
Sep 18, 2017 08:00 am ET
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
- BELLUS to provide BLU-5937 program update during September 20th webcast -- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -
Sep 06, 2017 08:00 am ET
BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017
- Key Opinion Leader Dr. Jacky Smith to present on chronic cough -- Company will also present an update on BLU-5937, a novel drug candidate for chronic cough -
Aug 09, 2017 08:00 am ET
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017
- Proceeds Received from Equity Sale Extend Cash Runway to 2019 -
Jun 19, 2017 08:00 am ET
May 09, 2017 06:00 pm ET
Apr 27, 2017 09:00 am ET
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 27, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including the recently in-licensed BLU-5937 program for chronic cough, on Monday May 1, 2017 at 11:30 am Eastern Time at the 2017 Bloom Burton & Co. Healthcare Investor Conference which will be held at the Sheraton Centre Toronto Hotel.
Apr 24, 2017 09:00 am ET
BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
- Composition of Matter Patent with Expiration Date in 2034 -
Mar 16, 2017 06:00 pm ET
Feb 28, 2017 11:07 am ET
IIROC Trade Resumption - BLU
TORONTO, Feb. 28, 2017 /CNW/ - Trading resumes in:
Feb 28, 2017 10:54 am ET
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016
LAVAL, QC, Feb. 28, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Feb 28, 2017 10:52 am ET
BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough
- Potential best-in-class drug candidate targetingthe clinically validated P2X3 receptor for chronic cough -- Potential to help millions of chronic cough patients,including those who do not respond to current therapies -
Feb 28, 2017 10:47 am ET
IIROC Trading Halt - BLU
TORONTO, Feb. 28, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 17, 2017 05:00 pm ET
Bellus Health Announces Payment to Thallion CVR Holders
The Company received funds in relation to the 2009 Thallion transaction and a payment of $577,152 will be made to the CVR holders on March 10, 2017
Dec 21, 2016 07:00 am ET
BELLUS Health provides update on pipeline
LAVAL, QC, Dec. 21, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, is providing an update on the projects in its pipeline.
Nov 10, 2016 07:00 am ET
BELLUS Health reports financial and operating results for the third quarter ended September 30, 2016
LAVAL, QC, Nov. 10, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the third quarter ended September 30, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Aug 09, 2016 08:00 am ET
BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016
LAVAL, QC, Aug. 9, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the second quarter ended June 30, 2016. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified.
Jun 20, 2016 09:00 am ET
BELLUS Health announces top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis
LAVAL, QC, June 20, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a drug development company focused on rare diseases, today announced top-line results from the Phase 3 study of KIACTA™ (eprodisate) for the treatment of AA amyloidosis.
Jun 02, 2016 08:00 am ET
BELLUS Health and Pharmascience announce scheduled conversion of Pharmascience's interest in BHI Limited Partnership
- Issuance of 6,350,638 common shares of BELLUS Health to Pharmascience upon conversion -
May 12, 2016 06:00 pm ET
BELLUS Health reports financial and operating results for the first quarter ended March 31, 2016
- Company also announces voting results from Annual Meeting of Shareholders -
Apr 26, 2016 08:00 am ET
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 26, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or "the Company"), a drug development company focused on rare diseases, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present an update on the Company's progress at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday May 2, 2016 at 10:30 am Eastern Time.
Feb 24, 2016 07:00 am ET
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2015
LAVAL, QC, Feb. 24, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a drug development company focused on rare diseases, today reported its financial and operating results for the year ended December 31, 2015.